Pharmacyclics Gets “Refuse To File” Letter On Xcytrin
This article was originally published in The Pink Sheet Daily
Executive Summary
Company had hoped for priority review when it submitted its NDA for treatment of brain metastases from non-small cell lung cancer in December.
You may also be interested in...
Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.
Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.
Pharmacyclics Taps Little-Used Regulatory Pathway For Xcytrin NDA
Firm’s decision to “file over protest” asks FDA to review NDA that received “refuse to file” letter in February.